First Opioid Trial Against Manufacturer by State Under Way in Oklahoma
In the first of many similar cases, the trial of Oklahoma versus Johnson & Johnson could frame who is to blame for the opioid epidemic.
Even after the Trump Administration declared the opioid epidemic a public health emergency in 2017, more than 130 people still die of opioid overdoses every day in the United States.
As providers and payers take steps to curb the epidemic, lawmakers are trying to determine who is to blame for the ongoing epidemic.
Part of that effort has been a recent surge of states suing pharmaceutical manufacturers, with states attempting to make them shoulder the costs of the opioid epidemic. Those costs are staggering: the average cost per overdose patient is $18,000, resulting in a $28.9 billion annual price tag for direct health costs alone.
As part of that trend, the state of Oklahoma is suing Johnson & Johnson, accusing them of using deceptive marketing techniques designed to drive use that in turn led to addiction. It will be the first case of the around 2,000 cases brought forth by state, local, and tribal governments to actually go to trial. Teva Pharmaceuticals and Purdue Pharma, also included in the suit, settled with the state earlier-Teva for $85 million last Sunday and Purdue for $270 million in March.
Related article: Independence Blue Cross President: How We Curb the Opioid Epidemic
Reggie Whitten, a lawyer for the state, told Reuters that the crisis could end up costing the state $13 billion over the next 20 years.
Larry Ottaway, a lawyer for Johnson & Johnson, in turn said that the company’s marketing did not differ from claims made by the FDA in 2009, which said that opioid rarely cause addiction if managed properly.
In a press release, Oklahoma Attorney General Mike Hunter said that he is looking forward to the trial, saying that “Nearly all Oklahomans have been negatively impacted by this deadly crisis and we look forward to [the trial], where we will prove our case against Johnson & Johnson and its subsidiaries.”
Nicholas Hamm is an editor with Managed Healthcare Executive
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
